Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.…
Cognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START Study
Cognition Therapeutics (NASDAQ: CGTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 14 employees.
The shares were at 0.5822 USD on 20 November 2026, down 64.9% over 52 weeks. Its 52-week range is 0.5500 USD to 1.825 USD: the price is 68.1% below the high and 5.9% above the low.
Its market capitalisation is 55.37M USD.
Cognition Therapeutics reports return on equity of -68.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 30.27M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.